Descriptor English: | Bortezomib | ||||
Descriptor Spanish: |
Bortezomib
| ||||
Descriptor Portuguese: | Bortezomib | ||||
Descriptor French: | Bortézomib | ||||
Entry term(s): |
341, PS LDP 341 LDP-341 LDP341 PS 341 PS-341 PS341 Velcade |
||||
Tree number(s): |
D01.029.260.110.500 D01.132.285.500 D02.203.200.500 D03.383.679.450 |
||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D000069286 | ||||
Scope note: | A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. |
||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||
Pharm Action: |
Antineoplastic Agents |
||||
Registry Number: | 69G8BD63PP | ||||
Public MeSH Note: | 2016; BORTEZOMIB was indexed under BORONIC ACIDS and PYRAZINES 2000-2015 |
||||
History Note: | 2016 (2000) |
||||
DeCS ID: | 55856 | ||||
Unique ID: | D000069286 | ||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||
Date Established: | 2016/01/01 | ||||
Date of Entry: | 2015/07/01 | ||||
Revision Date: | 2016/05/27 |
-
-
CHEMICALS AND DRUGS
Inorganic Chemicals [D01]Inorganic Chemicals -
CHEMICALS AND DRUGS
Inorganic Chemicals [D01]Inorganic Chemicals -
CHEMICALS AND DRUGS
Organic Chemicals [D02]Organic Chemicals -
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds
|
Bortezomib
- Preferred
LDP-341
- Narrower
PS 341
- Narrower
Velcade
- Narrower
Concept UI |
M0350110 |
Scope note | A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. |
Preferred term | Bortezomib |
Concept UI |
M0560884 |
Preferred term | LDP-341 |
Entry term(s) |
LDP 341 LDP341 |
Concept UI |
M0446631 |
Preferred term | PS 341 |
Entry term(s) |
341, PS PS-341 PS341 |
Concept UI |
M0446632 |
Preferred term | Velcade |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey